155 related articles for article (PubMed ID: 29648740)
1. Impact of a value-based formulary in three chronic disease cohorts.
Yeung K; Basu A; Marcum ZA; Watkins JB; Sullivan SD
Am J Manag Care; 2017 Mar; 23(3 Suppl):S46-S53. PubMed ID: 29648740
[TBL] [Abstract][Full Text] [Related]
2. Impact of a Value-based Formulary on Medication Utilization, Health Services Utilization, and Expenditures.
Yeung K; Basu A; Hansen RN; Watkins JB; Sullivan SD
Med Care; 2017 Feb; 55(2):191-198. PubMed ID: 27579915
[TBL] [Abstract][Full Text] [Related]
3. The impact of a value-based insurance design plus health coaching on medication adherence and medical spending.
Musich S; Wang S; Hawkins K
Popul Health Manag; 2015 Jun; 18(3):151-8. PubMed ID: 25247449
[TBL] [Abstract][Full Text] [Related]
4. Drug use and spending under a formulary informed by cost-effectiveness.
Yeung K; Cruz M; Tsiao E; Watkins JB; Sullivan SD
J Manag Care Spec Pharm; 2023 Nov; 29(11):1175-1183. PubMed ID: 37889867
[No Abstract] [Full Text] [Related]
5. Impact of a transition to more restrictive drug formulary on therapy discontinuation and medication adherence.
Shirneshan E; Kyrychenko P; Matlin OS; Avila JP; Brennan TA; Shrank WH
J Clin Pharm Ther; 2016 Feb; 41(1):64-9. PubMed ID: 26778812
[TBL] [Abstract][Full Text] [Related]
6. Association between dispensing channel and medication adherence among medicare beneficiaries taking medications to treat diabetes, high blood pressure, or high blood cholesterol.
Iyengar RN; Balagere DS; Henderson RR; LeFrancois AL; Rabbitt RM; Frazee SG
J Manag Care Spec Pharm; 2014 Aug; 20(8):851-61. PubMed ID: 25062079
[TBL] [Abstract][Full Text] [Related]
7. Designing a Value-Based Formulary for a Commercial Health Plan: A Simulated Case Study of Diabetes Medications.
Chen Y; Loucks AR; Sullivan SD; Pearson SD; Kent D; Yeung K
Value Health; 2023 Jul; 26(7):1022-1031. PubMed ID: 36796479
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of increased adherence and cost savings of an employer value-based benefits program targeting generic antihyperlipidemic and antidiabetic medications.
Clark B; DuChane J; Hou J; Rubinstein E; McMurray J; Duncan I
J Manag Care Pharm; 2014 Feb; 20(2):141-50. PubMed ID: 24456315
[TBL] [Abstract][Full Text] [Related]
9. Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia.
Li P; McElligott S; Bergquist H; Schwartz JS; Doshi JA
Ann Intern Med; 2012 Jun; 156(11):776-84, W-263, W-264, W-265, W-266, W-267, W-268, W-269. PubMed ID: 22665815
[TBL] [Abstract][Full Text] [Related]
10. Design, implementation, and first-year outcomes of a value-based drug formulary.
Sullivan SD; Yeung K; Vogeler C; Ramsey SD; Wong E; Murphy CO; Danielson D; Veenstra DL; Garrison LP; Burke W; Watkins JB
J Manag Care Spec Pharm; 2015 Apr; 21(4):269-75. PubMed ID: 25803760
[TBL] [Abstract][Full Text] [Related]
11. Increasing copayments and adherence to diabetes, hypertension, and hyperlipidemic medications.
Maciejewski ML; Bryson CL; Perkins M; Blough DK; Cunningham FE; Fortney JC; Krein SL; Stroupe KT; Sharp ND; Liu CF
Am J Manag Care; 2010 Jan; 16(1):e20-34. PubMed ID: 20059288
[TBL] [Abstract][Full Text] [Related]
12. Prescription co-pay reduction program for diabetic employees.
Nair KV; Miller K; Park J; Allen RR; Saseen JJ; Biddle V
Popul Health Manag; 2010 Oct; 13(5):235-45. PubMed ID: 20879904
[TBL] [Abstract][Full Text] [Related]
13. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
[TBL] [Abstract][Full Text] [Related]
14. Effect of a Remotely Delivered Tailored Multicomponent Approach to Enhance Medication Taking for Patients With Hyperlipidemia, Hypertension, and Diabetes: The STIC2IT Cluster Randomized Clinical Trial.
Choudhry NK; Isaac T; Lauffenburger JC; Gopalakrishnan C; Lee M; Vachon A; Iliadis TL; Hollands W; Elman S; Kraft JM; Naseem S; Doheny S; Lee J; Barberio J; Patel L; Khan NF; Gagne JJ; Jackevicius CA; Fischer MA; Solomon DH; Sequist TD
JAMA Intern Med; 2018 Sep; 178(9):1182-1189. PubMed ID: 30083727
[TBL] [Abstract][Full Text] [Related]
15. Impact of drug plans on adherence to and the cost of antihypertensive medications among patients covered by a universal drug insurance program.
Després F; Perreault S; Lalonde L; Forget A; Kettani FZ; Blais L
Can J Cardiol; 2014 May; 30(5):560-7. PubMed ID: 24613090
[TBL] [Abstract][Full Text] [Related]
16. Medication adherence star ratings measures, health care resource utilization, and cost.
Poonawalla IB; Chung L; Shetler S; Pearce H; Dixon SW; Racsa P
Am J Manag Care; 2024 May; 30(5):210-217. PubMed ID: 38748928
[TBL] [Abstract][Full Text] [Related]
17. Impact of a Combined Value-Based Insurance Design and Medication Therapy Management Program on Diabetes Medication Adherence.
Peaslee A; Wickizer M; Olson J; Topp R
J Manag Care Spec Pharm; 2016 Nov; 22(11):1303-1309. PubMed ID: 27783550
[TBL] [Abstract][Full Text] [Related]
18. The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs*.
Chapman RH; Ferrufino CP; Kowal SL; Classi P; Roberts CS
Int J Clin Pract; 2010 Jan; 64(2):169-81. PubMed ID: 20089007
[TBL] [Abstract][Full Text] [Related]
19. The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation.
Zeng F; An JJ; Scully R; Barrington C; Patel BV; Nichol MB
Value Health; 2010; 13(6):846-52. PubMed ID: 20561344
[TBL] [Abstract][Full Text] [Related]
20. Impact of primary care intensive management on medication adherence and adjustments.
Yoon J; Wu F; Chang E
Am J Manag Care; 2020 Aug; 26(8):e239-e245. PubMed ID: 32835465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
